Jiri Stork
Overview
Explore the profile of Jiri Stork including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
942
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sticova E, Kyclova J, Dura M, Stork J, Lipovy B
Cesk Patol
. 2023 Oct;
59(3):124-128.
PMID: 37805268
Stevens-Johnson syndrome and toxic epidermal necrolysis (Lyell syndrome) are rare diseases characterized by rapid blistering followed by extensive skin and mucosal exfoliation and constitutional symptoms. In most cases, drugs are...
2.
Dura M, Sticova E, Felsoova A, Stork J
Cesk Patol
. 2023 Oct;
59(3):104-123.
PMID: 37805267
The authors present a didactic overview of the most common inflammatory non-infectious skin diseases. This overview is not exhaustive, but illustrative, especially when regarding the aspect of a systematic approach...
3.
Dura M, Stork J, Felsoova A, Sticova E
Cesk Patol
. 2023 Oct;
59(3):96-103.
PMID: 37805266
Dermatopathology is a distinct part of pathology revealing the rich association with soft tissue pathology and hematopathology. Regarding the number and diversity of the skin disorders, dermatopathology is a broad...
4.
Dura M, Pock L, Cetkovska P, Jungova A, Nemejcova K, Stork J
J Cutan Pathol
. 2022 Mar;
49(8):717-721.
PMID: 35294059
Cutaneous collagenous vasculopathy (CCV) is an extremely rare acquired microangiopathy of unknown etiology. The authors describe a case of a 68-year-old man, a carrier of a heterozygous pathogenic variant of...
5.
Kodet O, Nemejcova K, Strnadova K, Havlinova A, Dundr P, Krajsova I, et al.
Int J Mol Sci
. 2021 Jul;
22(13).
PMID: 34281259
Therapy targeting immune checkpoints represents an integral part of the treatment for patients suffering from advanced melanoma. However, the mechanisms of resistance are responsible for a lower therapeutic outcome than...
6.
Plzakova Z, Bloomfield M, Polaskova S, Stork J, Honzik T
Pediatr Dermatol
. 2020 Jul;
37(4):e32-e34.
PMID: 32706466
No abstract available.
7.
Kodet O, Kucera J, Strnadova K, Dvorankova B, Stork J, Lacina L, et al.
Int J Oncol
. 2020 Jul;
57(3):619-630.
PMID: 32705148
The incidence of cutaneous malignant melanoma has been steadily increasing worldwide for several decades. This phenomenon seems to follow the trend observed in many types of malignancies caused by multiple...
8.
Kucera J, Strnadova K, Dvorankova B, Lacina L, Krajsova I, Stork J, et al.
Oncol Rep
. 2019 Sep;
42(5):1793-1804.
PMID: 31545456
The steadily increasing incidence of malignant melanoma (MM) and its aggressive behaviour makes this tumour an attractive cancer research topic. The tumour microenvironment is being increasingly recognised as a key...
9.
Kodet O, Dvorankova B, Bendlova B, Sykorova V, Krajsova I, Stork J, et al.
Int J Mol Med
. 2018 Feb;
41(5):2687-2703.
PMID: 29393387
The incidence of malignant melanoma is rapidly increasing and current medicine is offering only limited options for treatment of the advanced disease. For B‑Raf mutated melanomas, treatment with mutation‑specific drug...
10.
Elhai M, Meune C, Boubaya M, Avouac J, Hachulla E, Balbir-Gurman A, et al.
Ann Rheum Dis
. 2017 Aug;
76(11):1897-1905.
PMID: 28835464
Objectives: To determine the causes of death and risk factors in systemic sclerosis (SSc). Methods: Between 2000 and 2011, we examined the death certificates of all French patients with SSc...